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Abstract
Background: Risk stratification of patients in the emergency department can be strengthened using prognostic
biomarkers, but the impact on patient prognosis is unknown. The aim of the TRIAGE III trial was to investigate
whether the introduction of the prognostic and nonspecific biomarker: soluble urokinase plasminogen activator
receptor (suPAR) for risk stratification in the emergency department reduces mortality in acutely admitted patients.
Methods: The TRIAGE III trial was a cluster-randomized interventional trial conducted at emergency departments in
the Capitol Region of Denmark. Eligible hospitals were required to have an emergency department with an intake
of acute medical and surgical patients and no previous access to suPAR measurement. Three emergency departments
were randomized; one withdrew shortly after the trial began. The inclusion period was from January through June of
2016 consisting of twelve cluster-periods of 3-weeks alternating between intervention and control and a subsequent
follow-up of ten months. Patients were allocated to the intervention if they arrived in interventional periods, where
suPAR measurement was routinely analysed at arrival. In the control periods suPAR measurement was not performed.
The main outcome was all-cause mortality 10 months after arrival of the last patient in the inclusion period. Secondary
outcomes included 30-day mortality.
Results: The trial enrolled a consecutive cohort of 16,801 acutely admitted patients; all were included in the analyses.
The intervention group consisted of 6 cluster periods with 8900 patients and the control group consisted of 6 cluster
periods with 7901 patients. After a median follow-up of 362 days, death occurred in 1241 patients (13.9%) in the
intervention group and in 1126 patients (14.3%) in the control group.
The weighted Cox model found a hazard ratio of 0.97 (95% confidence interval, 0.89 to 1.07; p = 0.57). Analysis of all
subgroups and of 30-day all-cause mortality showed similar results.
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Conclusions: The TRIAGE III trial found no effect of introducing the nonspecific and prognostic biomarker suPAR in
emergency departments on short- or long-term all-cause mortality among acutely admitted patients. Further research
is required to evaluate how prognostic biomarkers can be implemented in routine clinical practice.
Trial registration: clinicaltrials.gov, NCT02643459. Registered 31 December 2015.
Keywords: Prognostic biomarkers, Risk stratification, Emergency department,
Background
In emergency departments (EDs) that serve a high num-
ber of patients, delays and crowding can increase mortality
[1–3]. ED patients present with all types of conditions,
ranging from minor injuries to life-threatening diseases,
and patient health status ranges from healthy to multi-
morbid. Thus, it is important to be able to distinguish
between patients that can wait for treatment and those
who are in need of immediate attention. Currently, many
EDs use triage algorithms based upon vital signs and
primary complaints to risk stratify patients.
Several studies have demonstrated that the prognostic
abilities of various biomarkers in acutely admitted
patients in improving risk assessment in EDs [4–9].
These biomarkers include lactate [10], copeptin [8, 9],
pro-adrenomedullin [5, 6, 11], albumin [12, 13],
C-reactive protein (CRP) [14, 15], and soluble urokinase
plasminogen activator receptor (suPAR) [16–20]. How-
ever, none of these studies have addressed whether risk as-
sessment that is strengthened by prognostic biomarkers
improves patient outcome. This trial investigated whether
using a biomarker to add prognostic information reduces
mortality in ED patients.
Based upon its performance in comparable cohorts of
unselected patients in EDs [16–18, 21], we used suPAR as
the prognostic biomarker in this trial. suPAR is the soluble
form of the cell membrane-bound protein uPAR, which is
expressed mainly on immune cells, endothelial cells, and
smooth muscle cells. uPAR is released during inflammation
or immune activation, and the suPAR level reflects the ex-
tent of immune activation in the individual [22]. Studies
have shown that the suPAR level is associated with morbi-
dity and mortality in several acute and chronic diseases,
cancer and in disease development in the general popula-
tion [20]. The suPAR level is elevated across diseases, while
low suPAR levels are associated with a low risk of morbidity
and mortality [17], enabling an identification of patients at
high and at low risk. Therefore, suPAR is applicable as a
nonspecific prognostic marker and not as a diagnostic
marker. In cohorts of ED patients, suPAR is associated with
length of hospital stay and readmission, transfer to the in-
tensive care unit (ICU), the presence and severity of acute
and chronic conditions, and risk of death [16–18, 20, 21].
We hypothesized that availability of suPAR would improve
patient prognosis.
The aim of this trial was to evaluate whether the intro-
duction of suPAR in the emergency departments would
improve risk stratification and lead to a reduction in
all-cause mortality 10 months after arrival.
Methods
Study design and setting
The TRIAGE III trial was a cross-over, cluster-randomized,
parallel-group, interventional trial. The hospitals were the
units of randomization, and the patients were the units of
analysis. The trial protocol was published previously [23].
The full protocol is included in Additional file 1. Using a
cluster design ensured that unselected patients with differ-
ent chronic and acute diseases were included in both
groups as consecutive cohorts with a high inclusion rate.
The trial was conducted in the Capital Region of Denmark,
and eligible hospitals were required to have an ED with
intake of both acute medical and surgical patients and no
previous access to suPAR measurement. The inclusion
criteria for the patients were age 16 years or older, acute
presentation at the ED, and having blood test results (in-
cluding haemoglobin, CRP, and creatinine level determi-
nation) within six hours of arrival to the ED. Patients were
treated at specialized areas of the ED depending on their
primary complaint. Admissions to the paediatric, obstetric,
and gynaecological departments were excluded.
Randomization
The participating EDs were randomized 1:1 to start as
either intervention or control with subsequent cross
over. The inclusion period consisted of twelve 3-week
clusters that alternated between intervention and control
periods at the two EDs. The investigators enrolled the EDs
and used computer-generated numbers for randomization
and allocation. Heads of the EDs provided consent before
randomization.
Intervention
In the intervention period, suPAR measurement was in-
cluded as a routine test as part of the panel of blood
tests that was analysed at arrival to the ED. The suPAR
result was presented to the doctors on monitors and in
the electronical patient journals within 2 h of blood
sampling. In the control periods, the suPAR level was
not measured. Blinding was not possible. Due to the
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nonspecific nature of suPAR, no formal intervention was
defined. Instead, we provided ED doctors with an estimate
of the prognosis using unadjusted mortality rates at diffe-
rent suPAR levels [23] and advised the doctors to incorpo-
rate the prognostic information conveyed by the suPAR
level into their clinical assessment. In addition, the doctors
were advised to conduct a more extensive assessment and
to search for unrecognized disease in patients who had
elevated suPAR levels for no obvious reason. In patients
with low suPAR levels, doctors were advised to consider
discharge if no other finding contradicted this. Further-
more, the ED nurses were advised to prioritise patients with
high suPAR levels. Prior to the study, doctors received
information regarding the prognostic abilities of suPAR,
including a summary of the existing literature and pocket
cards [23]. In addition, formalized teaching sessions were
carried out in participating departments [23].
Outcomes
The primary outcome was all-cause mortality assessed after
April 6, 2017, ten months after inclusion of the last patient
(median 12 months). The Secondary outcomes were I)
all-cause mortality 30 days after arrival to the ED; II) rapid
discharges (< 24 h) from the hospital; III) admissions to the
medical ward (all internal medicine specialities, including
admission in the “medical” area of the ED); IV) transfers to
the ICU; V) new (not previously registered) cancer diagno-
ses at the end of follow-up; VI) the length of the hospital
stay; and VII) readmission within 30 and 90 days. All out-
comes were assessed after data was available in July of 2017
and prespecified in the statistical analysis plan that was
published online on April 5, 2017 [24].
Data
All residents in Denmark are registered in the Danish
Civil Registration System (CRS) and have a unique
personal identification number that allows follow-up
through national registries. Vital status is registered in the
CRS, and all patient encounters within the secondary
health care system are registered in the Danish National
Patient Registry (DNPR) [25–27]. We acquired data on all
outcomes from the CRS and the DNPR after follow-up
was complete. Data from blood tests, including the plasma
suPAR level, was extracted from the hospitals laboratory
databases, via the Departments of Clinical Biochemistry.
The index ED visit was defined as the first visit during
the inclusion period. Readmissions was defined as a new
ED visit following discharge from the ED or a hospital
ward. For inclusion in the trial, patients were required to
have an encounter for an acute hospital visit registered
in the DNPR. The Charlson Comorbidity Index (Charlson
score) was calculated using a modified SAS macro [28, 29]
and based on all diagnoses in the NPR that were registered
two years prior to the index ED visit [16].
Statistical analysis
The trial was designed to have a power of 80% at a 5%
level of significance and an assumption of equal cluster
size to detect an absolute risk reduction in mortality of
1.5% 10 months after arrival of the last patient, with inclu-
sion of 7340 patients in each group. Patients admitted
during the intervention period without suPAR measure-
ment remained in the intervention group for analyses ac-
cording to the intention-to-treat principle. Continuous
variables are described by the median value and inter-
quartile range (IQR) and by the mean value and standard
deviation (SD). Categorical variables are described by
number (no.) and percentage (%). Comparing of secon-
dary outcomes was done using Student’s t-test, Fisher’s
test and Chi-square test. The statistical analysis plan is
provided in Additional file 1.
Primary outcome analyses
The main analysis of the primary outcome was performed
using a weighted Cox regression model with the time
since the index visit as the underlying scale. Patients who
were readmitted were re-weighted at their first ED visit
according to the probability of being included in the same
group as their index ED visit and were otherwise
censored. Subsequent readmissions did not influence
weighting or censoring. Robust standard errors were
employed to account for the clustering.
The following sensitivity analyses of the primary
outcome were performed: I) censoring in case of re-
admission instead of weighting and II) a weighted
analysis that excluded patients who did not receive
the intervention and patients from control periods
with an erroneous suPAR measurement (per proto-
col); III) a multivariate Cox model that was adjusted
for age, sex, Charlson score, hospital, and CRP level.
In addition, we performed pre-specified subgroup
analyses (hospital, age < 65, age ≥ 65, groups based on
discharge-diagnoses; cancer, cardiovascular disease,
infections, neurological disease and surgery during
admission) of the primary outcome [24].
Secondary outcome analyses
The secondary outcome of all-cause mortality at 30 days
was analysed similar to the primary outcome. The Stu-
dent’s t-test was used to compare the length of stay, and
the chi-square test or Fisher’s tests were used as appro-
priate to compare proportions. Readmissions were
assessed as proportions and, additionally, with a Cox
model, taking competing risks (death, readmissions)
into account. Prespecified subgroup analyses were
performed for the length of hospital stay, the propor-
tion of rapid discharges within 24 h, and readmissions
within 30 days [24].
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Prognostic value of suPAR
To evaluate if the prognostic value of suPAR was com-
parable to previous reports, we assessed the ability of
suPAR to discriminate between mortality rates at 30 days
and 10 months was assessed using the area under the
curve (AUC) for receiver operating characteristics
(ROC) curves as well as using a Cox model that was
stratified by suPAR quartiles. The median suPAR levels
between survivors and non-survivors were compared
using the Wilcoxon rank-sum test.
Evaluation of the intervention
To assess whether the intervention was successful and
to evaluate whether the suPAR level was noticed and
acted upon, we conducted an anonymous web-based
questionnaire of 200 randomly selected ED doctors at
the participating hospitals.
P < 0.05 was considered statistically significant. Statistics
were performed in R version 3.2.3 (The R Foundation for
Statistical Computing), and figures were created with R and
GraphPad Prism, version 7.02 (GraphPad Software, Inc.).
All of the analyses were stipulated in the statistical analysis
plan that was published online on April 5, 2017 [24].
Results
Trial population
Of four eligible hospitals in the Capital Region of
Denmark, one already performed suPAR measurement
as a routine test and was therefore excluded, and the
other three agreed to participate in the trial. One
hospital withdrew from the trial shortly after the inclu-
sion period began for internal administrative reasons.
Thus, inclusion took place at two EDs at Bispebjerg
Hospital and Herlev Hospital, which have annual admis-
sions of 70,000 and 85,000, respectively. Patients were
included as planned from January 11, 2016 until June 6,
2016 with a subsequent 10-month follow-up that was
concluded on April 6, 2017.
Data were collected for 31,570 ED visits of 17,451 individ-
ual patients. After data management and the application of
inclusion- and exclusion criteria, 26,653 ED visits of 16,801
unique patients was admitted (Fig. 1). Median age was
64 years (IQR, 45 to 77), 8864 (53%) were female. The inter-
vention group consisted of 8900 patients compared to the
control group of 7901. In the intervention group 1002 pa-
tients (11.3%) did not have a suPAR measurement available,
while suPAR was erroneously measured in seven patients
Fig. 1 CONSORT flow diagram of the TRIAGE III trial population of patients acutely admitted. EDs: emergency departments, DNPR: National
Patient Registry, LABKA: Electronical laboratory database. Full CONSORT checklist is provided in Additional file 3
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(0.1%) in the control group. The baseline characteristics
were similar in the groups (Table 1). Comparison at the
cluster level revealed small differences (Additional file 2:
Table S1).
Primary outcome
The median follow-up in the intervention group was
362 days (IQR 325 to 397 days) and 362 (IQR 325 to
414 days). All-cause mortality as assessed at the end of
follow-up occurred in 1241 patients (13.9%) in the inter-
vention group and in 1126 patients (14.3%) in the
control group. The primary weighted Cox analysis of
all-cause mortality according to the intention-to-treat
principle found no significant difference between the
intervention group and the control group with a hazard
ratio (HR) of 0.97 (95% confidence interval (CI) 0.89 to
1.07; p = 0.57) (Fig. 2).
None of the sensitivity and subgroup analyses, includ-
ing the per-protocol and fully adjusted model showed
any significant differences between the intervention and
control groups (Fig. 3 and Additional file 2: Table S2).
Secondary outcomes
Repeating the primary analysis, using all-cause mortality
at 30 days showed no significant difference between
groups (HR, 0.98; 95% CI, 0.84 to 1.16; p = 0.84). There
was no significant difference between groups in the pro-
portion of patients discharged within 24 h (intervention
49.8% vs. control 48.9%; absolute difference: 0.9%; 95%
CI, − 0.62 to 2.42, p = 0.23). Similarly, we observed no
significant difference in the mean (SD) length of hospital
stay (intervention 4.39 days (8.27) vs. control 4.53 days
(8.70); difference: 0.14 days; 95% CI, − 0.12 to 0.40,
p = 0.29), nor in mean (SD) length of ED stay (inter-
vention 4.4 h (16.5) vs. control 4.5 h (9.2), p = 0.61),
and transfers to the ICU were equal in both groups
(1.3%, p = 0.91). There was no difference in the fre-
quency of newly diagnosed cancers at the end of the
follow-up (intervention 8.7% vs. control 8.9%, p = 0.79).
The proportion of admissions to the medical ward (in-
cluding visits in the medical area of the ED) was signifi-
cantly lower in the intervention group compared to the
control group (44.3% vs. 42.0%, p = 0.003).
We observed a significantly higher proportion of read-
missions in the intervention group at 30 days (interven-
tion 10.3% vs. control 8.7%, p = 0.01), but not at 90 days
(18.7% vs. 18.4%, p = 0.95). Cox analyses with competing
risks showed the same associations: the HR for readmis-
sion risk at 30 days compared with the control group
was 1.16 (95% CI, 1.05 to 1.28, p = 0.003) and the HR
for readmission risk at 90 days was 1.02 (95% CI, 0.94 to
1.10, p = 0.64). The subgroup analyses are shown in
Additional file 2: Table S3.
Discriminative abilities of suPAR
The median suPAR level of patients who survived was sig-
nificantly lower than in patients who died during follow-up,
both within 30 days (4.0 ng/ml (IQR 2.9–5.7 ng/mL) vs.
8.3 ng/ml (IQR 5.9 to 11.7 ng/mL), p < 0.001) and at the
end of follow-up (3.8 ng/ml (IQR 2.8 to 5.3 ng/mL) vs.
6.9 ng/ml (IQR 5.1 to 10.1 ng/mL), p < 0.001) Stratifying
patients by suPAR quartiles revealed strong discriminative
abilities regarding all-cause mortality during follow-up
(Additional file 2: Figure S1). The prognostic power for pre-
dicting 30-day and 10-month mortality was also high, with
AUCs (95% CI) of 0.83 (0.81 to 0.84) and 0.80 (0.7 to 0.82),
respectively, which were higher than for other biomarkers
and age (Fig. 4).
Table 1 Characteristics of the acutely admitted patients at
index ED visit at the emergency department
Intervention
(N = 8900)
Control
(N = 7901)
Hospital, number patients (%)
Bispebjerg Hospital 3451
(38.8%)
3569 (45.2%)
Herlev Hospital 5449
(61.2%)
4332 (54.8%)
Patients
Female sex, no. (%) 4689
(52.7%)
4175 (52.8%)
Age (years), mean (SD) 60.4 (20.8) 60.9 (20.7)
Charlson score, mean (SD) 0.7 (1.5) 0.7 (1.5)
Length of hospital stay (days), mean
(SD)
4.4 (8.3) 4.5 (8.7)
In-hospital admission, no. (%) 4461 (50.1) 4031 (51.0)
Biomarkers, median (IQR)
Albumin (g/L) 39 (35 to
43)
39 (34 to 42)
Creatinine (μmol/L) 76 (62 to
94)
75.0 (62 to
93)
CRP (mg/L) 5.0
(3.0 to 39.0)
5.0
(3.0 to 41.0)
Haemoglobin (mmol/L) 8.3
(7.5 to 9.0)
8.3
(7.6 to 9.1)
suPAR (ng/ml) 4.1
(2.9 to 6.0)
n.a.
Subgroups, diagnoses at discharge
Cancer, no. (%) 559 (6.3%) 471 (6%)
Cardiovascular disease, no. (%) 1918
(21.6%)
1726 (21.8%)
Infections, no. (%) 1676
(18.8%)
1584 (20%)
Neurological disease, no. (%) 936 (10.5%) 864 (10.9%)
Surgery during admission, no. (%) 876 (9.8%) 787 (10%)
CRP C-reactive protein, IQR interquartile range, SD standard deviation, suPAR
soluble urokinase plasminogen activator receptor
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Results of the questionnaire
Among responders (n = 85), 89.4% noticed the suPAR
level and 89.5% replied that they felt informed about its
prognostic abilities. When asked whether suPAR influ-
enced clinical decision making, 4.4% replied that it did
in more than 20% of cases, 16.2% replied that it did in
10% to 20% of cases, while 79.4% replied that it did in less
than 10% of cases or never (Additional file 2: Figure S2).
Discussion
The TRIAGE III trial is the largest prospective trial and
the first interventional trial to test the effects of introdu-
cing a prognostic biomarker in emergency medicine. We
found that the introduction of the nonspecific biomarker
suPAR for risk stratification in the ED had no effect on
all-cause mortality.
There was no significant difference between the inter-
vention and control groups for any of the predefined
clinical outcomes or subgroups, except for a higher pro-
portion of admissions to the medical ward in the control
group and a higher risk of readmissions at 30 days in the
intervention group. However, readmission risk according
to group was opposite at the two hospitals, and there
was no association with the risk of readmission at
90 days, indicating that this was a chance finding.
The trial was designed to investigate whether the avail-
ability of biomarker-based prognostic information improves
outcome. It has previously been hypothesized, but never
shown, that adding a prognostic biomarker would
strengthen risk stratification and lead to improved patient
outcome and flow in the ED [5, 6, 11]. In addition, early
risk stratification has previously been suggested to improve
patient outcome in some conditions, such as, sepsis
[30–32] and myocardial infarction [33–35]. This is
plausible, as patients could receive relevant treatment
faster or be discharged without being exposed to the
risks of hospitalization. However, our findings suggest
that enhanced early risk stratification using suPAR
did not provide additional information beyond clinical
appearance and usual diagnostics in the current
design that was translatable to interventions capable
of influencing patient prognosis.
Strengths and limitations
Strengths of the trial include the consecutively included
and unselected cohort of medical and surgical patients from
two large EDs, indicating high generalizability. In addition,
the pragmatic cluster design of the trial ensured inclusion
of a full cohort and optimal conditions to investigate the
effect of the introduction of a prognostic biomarker. The
doctors were provided with the blood level of suPAR, a
strong prognostic biomarker, within 2 h of arrival, and our
results demonstrated prognostic capabilities of suPAR simi-
lar to previous reports [17, 21]. The introduction of suPAR
allowed for an enhanced early risk assessment, dividing
patients into high and low risk groups.
0 50 100 150 200 250 300 350
0.
85
0.
90
0.
95
1.
00
Days since index admission
S
ur
vi
va
l
control
intervention
Fig. 2 Kaplan-Meier plot displaying survival until end of follow-up. The Kaplan-Meier plot shows survival of patients acutely admitted to two
emergency departments stratified by intervention period (measurement of soluble urokinase plasminogen activator receptor, suPAR) and control
period (no suPAR measurement). Log-rank test: P = 0.61
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Fig. 3 Plot of all Cox regressions from the TRIAGE III trial. Patients acutely admitted to two emergency departments were allocated to
intervention (measurement of soluble urokinase plasminogen activator receptor (suPAR)) or control (no suPAR measurement). The red squares
indicate point estimates and the black horizontal lines indicate 95% confidence intervals (CIs). The figure shows hazard ratios based on
unadjusted weighted Cox regression models with all-cause mortality at the end of follow-up. The primary outcome of all-cause mortality assessed
at the end of follow-up and sensitivity analyses (censoring and per-protocol) are included, as are the subgroups, including cluster and age. The
unadjusted model with 30-day all-cause mortality as outcome is also included
Fig. 4 The area under the curve for mortality in patients acutely admitted. Comparison of prognostic ability of four biomarkers and age at 2 days,
30 days, 60 days, 90 days, and at the end of follow-up. suPAR vs. CRP, all time points: P < 0.001. suPAR vs. haemoglobin, all time points: P < 0.001.
SuPAR vs albumin: 2 days: P = 0.37, suPAR vs. albumin at other time points: P < 0.001. CRP: C-reactive protein, suPAR: soluble urokinase
plasminogen activator receptor
Schultz et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2018) 26:69 Page 7 of 10
The trial has several limitations. Biomarker-based
prognostic information will only have an impact on
outcomes if it is used and if it provides information that
is not already obvious based on the patient’s clinical
appearance or on other routine tests. Although 11.3% of
suPAR measurements were missing and the response
rate of the questionnaire was unsatisfactory, most
respondents replied that they noticed the suPAR level,
indicating that the intervention was sufficiently imple-
mented. However, it is an important limitation to the
trial that we were not able to explore the changes in
clinical decision-making further or on an individual
level, as our trial was designed to solely collect follow-up
data from the National Registries, which does not
include this information on clinical behaviour or single
clinical interventions. Furthermore, the trial only in-
cluded patients who had results of the routine blood
tests available, thus the results are not transferable to pa-
tients with no indication for blood tests. Missing suPAR
measurements in the intervention group might intro-
duce selection bias, but the per-protocol analysis showed
no effect on mortality in accordance with the ITT ana-
lyses, indicating no such bias in our data. Interventions
based on the suPAR level also incorporated other clinical
findings that might have made the prognostic informa-
tion of suPAR unnecessary. Results from the question-
naire indicate that the suPAR level only influenced
clinical decision-making in a small proportion of cases;
thus, the possible effect was limited. Furthermore, due
to the nonspecific nature of suPAR, there was no prede-
fined single intervention usable for all patients and the
doctors had to act differently in every case depending on
the patient and the suPAR level. Doctors also had to rely
on written information and on short presentations about
how to interpret the suPAR level. It is possible that
providing more information, holding courses, or using a
longer implementation phase could maximize any po-
tential effect. Finally, the impact of using suPAR might
be clearer if we performed serial measurements, if we
used a well-defined intervention based on the suPAR
level, or if we assigned follow-up to patients with
elevated suPAR levels.
The theoretical enhancement of biomarker-based risk
stratification and subsequent improved prognosis is yet
to be substantiated. The optimal approach for risk strati-
fication would be an individually designed diagnostic
strategy and clinical assessment at arrival, but this is
often not feasible in a busy ED. Hence, there is still need
for accurate tools for risk stratification. A single marker
might not be applicable for all patients, but there could
still be use for prognostic biomarkers in emergency
medicine in selected conditions, in designs with clearly
defined interventions, or if we focused on the negative
predictive value for rapid discharge. However, this was
beyond the scope of this trial, and future interventional
studies are needed to evaluate how prognostic bio-
markers can be implemented in routine clinical practice.
Conclusion
The introduction of the nonspecific and prognostic bio-
marker suPAR in EDs did not affect short- or long-term
all-cause mortality among unselected acutely admitted
patients. Further research is required to evaluate how
prognostic biomarkers can be implemented in routine
clinical practice.
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